Author

Maria T. Abreu

Closing the gap: Negotiating for physicians and scientists
Closing the gap: Negotiating for physicians and scientists

Maria T. Abreu

Transition to digital healthcare & research: What do we keep and what do we forget?
Transition to digital healthcare & research: What do we keep and what do we forget?

Maria T. Abreu

Anti-TNF-still the best option in ulcerative colitis?
Anti-TNF-still the best option in ulcerative colitis?

Maria T. Abreu

JAK-ING UP THE BAR: “Can targeted inhibition of JAK/STAT signalling improve patient outcomes (AbbVie)
JAK-ING UP THE BAR: “Can targeted inhibition of JAK/STAT signalling improve patient outcomes (AbbVie)

Maria T. Abreu  et al.

EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION
EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION

Maria T. Abreu  et al.

EFFECT OF USTEKINUMAB MAINTENANCE THERAPY ON STOOL FREQUENCY AND RECTAL BLEEDING THROUGH 2 YEARS IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECT OF USTEKINUMAB MAINTENANCE THERAPY ON STOOL FREQUENCY AND RECTAL BLEEDING THROUGH 2 YEARS IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Maria T. Abreu  et al.

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY
PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

Maria T. Abreu  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Maria T. Abreu  et al.

BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

Maria T. Abreu  et al.

TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Maria T. Abreu  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Maria T. Abreu  et al.

HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS AN EMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE
HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS AN EMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE

Maria T. Abreu  et al.

GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Maria T. Abreu  et al.

EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

Maria T. Abreu  et al.

SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL
SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

Maria T. Abreu  et al.

CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION
CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION

Maria T. Abreu  et al.

PATIENTS WITH FIBROSTENOTIC CROHN’S DISEASE CAN TOLERATE A HIGH-FIBER, LOW-FAT DIET AND EXPERIENCE AN IMPROVEMENT IN SYMPTOMS: RESULTS OF A CATERED DIET INTERVENTION STUDY
PATIENTS WITH FIBROSTENOTIC CROHN’S DISEASE CAN TOLERATE A HIGH-FIBER, LOW-FAT DIET AND EXPERIENCE AN IMPROVEMENT IN SYMPTOMS: RESULTS OF A CATERED DIET INTERVENTION STUDY

Maria T. Abreu  et al.

INTERROGATION OF DIET-INDUCED CHANGES IN THE MICROBIOME USING METAPROTEOMIC ANALYSIS OF CROHN’S DISEASE PATIENTS RECEIVING A CATERED HIGH FIBER, LOW FAT DIET INTERVENTION
INTERROGATION OF DIET-INDUCED CHANGES IN THE MICROBIOME USING METAPROTEOMIC ANALYSIS OF CROHN’S DISEASE PATIENTS RECEIVING A CATERED HIGH FIBER, LOW FAT DIET INTERVENTION

Maria T. Abreu  et al.

EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION
EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION

Maria T. Abreu  et al.

SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS
SAFETY OF USTEKINUMAB IN OLDER IBD PATIENTS (>=60 YEARS): POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC AND ALL APPROVED INDICATIONS

Maria T. Abreu  et al.

Item 1 - 20 / 20
1